Home RF & Microcurrent Device Patents: Who Leads 2026
Home radiofrequency and microcurrent device patents: who holds the claims
85.1% concentration. The top 5 of 12 ranked assignees account for 97 of the 114 records in scope — filing here is dominated by a small group, not a fragmented field. Filings rose from 15 in 2017 to a peak of 37 in 2019, then eased back. The 2021-to-2024 window shows a 23% decline, from 13 to 10 records. 2025 and 2026 figures are undercounted because publication typically lags filing by around 18 months, so the most recent two years should not be read as a continued drop.
- 1I LUMEN SCI INC33.3%
- 2NSE PRODUCTS INC21.9%
- 3MACUMIRA MEDICAL DEVICES INC12.3%
- 4NEWMARK12.3%
- 5NOVA OCULUS CANADA MFG ULC5.3%
See the full home radiofrequency and microcurrent devices analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in home radiofrequency and microcurrent devices?
The assignee ranking in this dataset returns 12 companies, and the field is heavily concentrated: the top 5 of those 12 hold 97 of the 114 records in scope, or 85.1%. The single leading assignee alone accounts for 38 records, well ahead of the fifth-ranked name at 6. This means competitive analysis in this space should focus on a small set of established portfolios rather than a broad field of filers.
Is patent filing in this space growing or slowing down?
Filing peaked in 2019 at 37 records and has since eased; the most recent complete comparison window, 2021 to 2024, shows a 23% decline from 13 to 10 records. However, publication typically lags filing by around 18 months, so the 2025 and 2026 figures in this dataset are undercounted and should not be read as confirmation the field has gone quiet. A fair read is that the field has cooled from its 2019 peak, with the last two years still an open question.
What technology areas dominate the patent claims in this field?
A61N, the electrotherapy and radiation therapy class, appears in 96.5% of the 114 records in scope, making it the near-universal claim category for this technology. Smaller but consistent shares go to healthcare informatics and digital data processing, each around 14.0%, and physical therapy or massage claims at 9.6%. Diagnostic, implant, and medicinal-preparation classes each sit under 6%, indicating those are minor overlaps rather than core claim areas.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Home Radiofrequency and Microcurrent Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.